Trials / Completed
CompletedNCT01169792
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to * evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and * analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tamoxifen |
Timeline
- First posted
- 2010-07-26
- Last updated
- 2010-07-26
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01169792. Inclusion in this directory is not an endorsement.